Design Therapeutics (DSGN) Invested Capital (2020 - 2026)

Design Therapeutics' Invested Capital history runs 7 years deep, the most recent figure standing at $218.1 million for Q1 2026.

• In Q1 2026, Invested Capital fell 4.33% year-over-year to $218.1 million; the TTM figure through Mar 2026 stood at $218.1 million (down 4.33% YoY), while the FY2025 annual figure was $212.5 million, down 12.22% from the prior year.
• Invested Capital came in at $218.1 million for Q1 2026 at Design Therapeutics, up from $212.5 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $370.3 million in Q1 2022 to a low of $199.7 million in Q3 2025.
• A 5-year average of $274.4 million and a median of $269.6 million in 2024 frame the typical range for Invested Capital.
• Across the five-year window, Invested Capital fell 20.89% in 2025 and decreased 4.33% in 2026, its largest moves.
• Design Therapeutics' Invested Capital stood at $327.3 million in 2022, then retreated by 15.16% to $277.7 million in 2023, then retreated by 12.82% to $242.1 million in 2024, then fell by 12.22% to $212.5 million in 2025, then rose by 2.61% to $218.1 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $218.1 million, $212.5 million, and $199.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison